📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-22 05:24
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Innova Captab approves brownfield expansion at Baddi plant and revises FY26 audited results
Innova Captab Limited's Board of Directors has approved a brownfield expansion of its existing manufacturing facility located at Baddi, Himachal Pradesh. Additionally, the Board approved revised audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditor, B S R & Co. LLP, issued an unmodified audit opinion on the revised consolidated annual results. The expansion aims to boost manufacturing throughput within the existing premises.
Confidence: MEDIUM
What changedInnova Captab approved a brownfield manufacturing capacity expansion at Baddi and adopted revised audited annual financial statements for FY26.
Why it mattersThe brownfield expansion within existing premises enables incremental CDMO and formulations production capacity with lower lead time and capex compared to greenfield setups.
Expansion Location: Baddi, Himachal PradeshFY26 Revised Results Approval Date: 21st August, 2026Capex outlay / Capacity addition: not disclosed
📅 Short termMarket sentiment is likely to view the expansion approval favorably, while investors review the detailed notes to assess reasons behind the FY26 financial revisions.
📈 Long termEnhances manufacturing scale to support company's stated generic formulations and CDMO growth pipeline alongside the recently operationalized Kathua facility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution timeline and cost escalation risks for brownfield construction
- Reasons for revising full-year audited financial results warrant monitoring
Key Highlights
Board approved brownfield capacity expansion at existing facility situated at 81-B, EPIP Phase-I, Jharmajri, Baddi, HP
Approved revised audited Standalone and Consolidated financial statements for FY ended March 31, 2026
Statutory auditor B S R & Co. LLP issued an unmodified audit report on the revised FY26 results
Board meeting commenced on August 21, 2026 at 23:16 IST and concluded on August 22, 2026 at 00:25 IST
👀 What to Watch
Track subsequent disclosures regarding the specific capex outlay, capacity addition metrics, and commissioning timelines for the Baddi brownfield expansion.
Innova Captab Approves Baddi Brownfield Expansion and Revises FY26 Financial Results
Innova Captab's Board has approved a brownfield expansion at its existing manufacturing unit in Baddi, Himachal Pradesh. Additionally, the Board approved revised audited standalone and consolidated financial statements for the quarter and year ended March 31, 2026. Statutory auditors B S R & Co. LLP provided an independent auditor's report, and the CFO submitted a declaration of unmodified opinion. The meeting commenced on August 21, 2026, at 23:16 IST and concluded on August 22, 2026, at 00:25 IST.
Confidence: HIGH
What changedThe Board sanctioned a brownfield expansion at the Baddi plant and formally approved revised audited financial statements for FY26.
Why it mattersThe brownfield expansion will add manufacturing capacity at the Baddi site to support growth, while unmodified audit opinion on revised FY26 results maintains reporting compliance.
Baddi Expansion Type: BrownfieldFiscal Year Revised: FY 2025-26TTM Revenue: Rs 5779 CrMarket Cap: Rs 20150 Cr
📅 Short termMarket focus will be on the operational details, capex quantum of the Baddi brownfield expansion, and reasons behind the restatement/revision of FY26 figures.
📈 Long termIncremental capacity at Baddi aligns with the company's multi-facility CDMO growth strategy alongside the recently operationalized Jammu plant.
⚠ Risk flags
- Lack of detailed capex budget and completion timeline in the main filing body
- Reasons for revision of audited annual financial statements need scrutiny
Key Highlights
Approved brownfield capacity expansion within existing premises at 81-B, EPIP Phase-I, Jharmajri, Baddi, HP
Adopted revised audited standalone and consolidated annual financial statements for FY26 (ended March 31, 2026)
Auditors B S R & Co. LLP issued audit report with an unmodified opinion on the revised consolidated annual figures
Consolidated entities covered include Univentis Medicare, Univentis Foundation, and step-down unit Sharon Bio-Medicine
👀 What to Watch
Track disclosures regarding the exact capex outlay and commercial timeline for the Baddi brownfield expansion, along with specifics on why FY26 financial statements were revised.
Innova Captab Q1 Concall: Revenue Up 34% YoY to ₹470.9 Cr, PAT Rises 42% to ₹44.1 Cr
Innova Captab delivered strong Q1 FY27 results with consolidated revenue increasing 34% YoY to ₹470.9 Cr, driven by robust performance across both CDMO (₹328.7 Cr, +32% YoY) and branded generics (₹142.2 Cr, +39% YoY). EBITDA rose 33% YoY to ₹75.1 Cr with a 16.0% margin, while PAT expanded 42% YoY to ₹44.1 Cr. Management reiterated full-year FY27 guidance of 20%+ volume-led revenue growth with profitability expected to outpace revenue. The new Jammu manufacturing facility is currently operating at 25%-30% capacity utilization on an annualized basis, with management targeting >₹1,000 Cr in revenue at steady-state utilization.
Confidence: HIGH
What changedInnova Captab published the detailed transcript of its Q1 FY27 earnings call held on August 12, 2026.
Why it mattersDemonstrates sustained operating leverage in core CDMO operations and provides clear operational milestones for the newly commissioned Jammu plant.
Q1 FY27 Revenue: ₹470.9 CrQ1 Revenue Growth YoY: 34%Q1 FY27 PAT: ₹44.1 CrQ1 FY27 EBITDA Margin: 16%Jammu Plant Target Revenue: INR1,000 crores
📅 Short termPositive sentiment driven by healthy 42% PAT growth and reaffirmation of 20%+ revenue growth guidance for FY27.
📈 Long termRamping up the Jammu greenfield unit to >₹1,000 Cr revenue and securing global product approvals provide strong structural growth visibility.
⚠ Risk flags
- Execution and regulatory approval timelines for new product filings at the Jammu plant
- Volatility in raw material/API prices impacting contract margins
Key Highlights
Q1 FY27 consolidated revenue rose 34% YoY to ₹470.9 Cr, with export revenue accounting for 32%
EBITDA grew 33% YoY to ₹75.1 Cr (16.0% margin), while PAT increased 42% YoY to ₹44.1 Cr
CDMO segment revenue stood at ₹328.7 Cr (+32% YoY); Branded Generics reached ₹142.2 Cr (+39% YoY)
Jammu facility utilization is at 25%-30% annualized, targeting >3x asset turn and >₹1,000 Cr long-term revenue
👀 What to Watch
Monitor quarterly capacity ramp-up and international regulatory approvals for the Jammu facility to verify sustained 20%+ growth delivery.
34% Revenue Growth in Q1 FY27: Innova Captab Ramps Up Jammu Facility and CDMO Segment
Innova Captab reported a strong start to FY27 with Q1 revenue growing 34% YoY to ₹470.9 Cr, driven by robust performance in both CDMO (+32%) and Branded Generics (+39%) segments. The company is benefiting from the ramp-up of its Jammu facility, which was commercialized in January 2025, and recent global certifications from UK-MHRA and PIC/S. Consolidated FY26 revenue reached ₹1,630 Cr with an EBITDA margin of 15.4%. The CDMO segment remains the primary growth engine, contributing approximately 70% of total quarterly revenue.
Confidence: HIGH
What changedThe company has successfully transitioned its new Jammu facility into commercial operations, leading to a significant 34% YoY revenue jump in the first quarter of FY27.
Why it mattersThe expansion and recent international regulatory approvals (UK-MHRA) allow the company to target higher-margin regulated markets and larger global CDMO contracts, potentially re-rating its growth profile.
Q1 FY27 Revenue: ₹470.9 CrYoY Revenue Growth: 34%CDMO Revenue Contribution: 70%FY26 EBITDA Margin: 15.4%Debt/Equity (FY26): 0.31
📅 Short termPositive sentiment is expected due to strong double-digit growth across all business segments and successful regulatory inspections, which validates the company's quality standards.
📈 Long termStructural growth is supported by the Jammu plant's capacity and expansion into regulated markets like the UK and Ukraine, diversifying the revenue base beyond domestic CDMO.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Working capital pressure due to increased inventory for the Jammu plant
- API price volatility impacting CDMO contract values
- Execution risk in international market expansion
Key Highlights
Q1 FY27 revenue increased 34% YoY to ₹470.9 Cr from ₹351.5 Cr in Q1 FY26
CDMO Services & Products revenue grew 32% YoY to ₹328.7 Cr, contributing 70% of total revenue
Branded Generics revenue surged 39% YoY to ₹142.2 Cr, supported by deeper market penetration
Jammu facility (4 manufacturing blocks) is witnessing a steady ramp-up following its Jan 2025 commercialization
FY26 consolidated EBITDA stood at ₹250.3 Cr with a margin of 15.4%
👀 What to Watch
Investors should monitor the utilization rates and margin progression of the Jammu facility as it scales. The impact of recent UK-MHRA and PIC/S (Ukraine) certifications on international order flows will be a key metric for long-term growth.
42.3% PAT Growth in Q1 FY27; Revenue up 34% to ₹470.9 Cr
Innova Captab reported a strong start to FY27 with consolidated revenue growing 34% YoY to ₹470.9 crore. Net profit (PAT) increased by 42.3% to ₹44.1 crore, driven by steady order flows and a broader product portfolio. EBITDA margins remained stable at 16.0%, despite a slight 10 bps dip from the previous year. The company highlighted the steady ramp-up of its Jammu facility and increased engagement with its 350+ client base.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing significant double-digit growth in both top-line and bottom-line compared to the same period last year.
Why it mattersThe results demonstrate successful execution of the Jammu plant ramp-up and the ability to maintain margins while scaling the CDMO and branded generics businesses.
Revenue (Q1 FY27): ₹470.9 crPAT (Q1 FY27): ₹44.1 crYoY Revenue Growth: 34.0%EBITDA Margin: 16.0%Q1 Revenue vs FY26 Revenue: 28.9%
📅 Short termPositive sentiment is expected in the short term due to strong YoY growth and stable margins, indicating operational efficiency.
📈 Long termStructural growth is supported by the Jammu facility expansion and entry into regulated markets like the UK, which could improve the product mix and margins over time.
⚠ Risk flags
- API price volatility impacting CDMO contract values
- Execution risk in international market expansion
Key Highlights
Revenue from operations grew 34.0% YoY to ₹470.9 crores compared to ₹351.5 crores in Q1 FY26.
PAT increased by 42.3% YoY to ₹44.1 crores from ₹31.0 crores.
EBITDA grew 32.7% to ₹75.1 crores with a margin of 16.0%.
The company now serves over 350 clients across its CDMO and branded generics businesses.
Jammu facility is witnessing a steady ramp-up with new client onboarding and increased business from existing customers.
👀 What to Watch
Monitor the utilization levels and margin trajectory of the Jammu facility as it scales up. Watch for further international market entries following the successful UK-MHRA inspection mentioned in the company profile.
Innova Captab Q1 Standalone PAT Jumps 58% to ₹32.06 Cr; FY26 Financials to be Revised
Innova Captab reported a strong standalone performance for Q1 FY27 (ending June 2026), with revenue rising 39.5% YoY to ₹400.48 Cr. Standalone PAT grew 58% YoY to ₹32.06 Cr, driven by operational scaling. However, the company disclosed that 'inadvertent errors' were identified in the previously approved FY26 financial statements (both standalone and group), necessitating a formal revision. While management claims no material impact on Q1 FY27 results, the revision details are pending the next board meeting.
Confidence: HIGH
What changedThe company reported its Q1 FY27 earnings and simultaneously announced a pending revision of its audited FY26 financial statements due to identified errors.
Why it mattersStrong double-digit growth in the standalone CDMO business confirms operational momentum, but the revision of audited financials is a governance monitorable that could affect investor sentiment.
Standalone Revenue (Q1 FY27): ₹400.48 CrStandalone PAT (Q1 FY27): ₹32.06 CrYoY Revenue Growth: 39.5%YoY PAT Growth: 58.0%Q1 Revenue vs TTM Consolidated Revenue: ~7.1%
📅 Short termThe strong earnings growth is a positive catalyst, but the disclosure of accounting errors in FY26 may lead to short-term volatility until the revised statements are published.
📈 Long termThe company's expansion into international markets (UK-MHRA, Ukraine) and the Jammu facility ramp-up remain the primary long-term value drivers, provided governance standards remain stable.
⚠ Risk flags
- Revision of previously audited financial statements due to errors
- Rising finance costs (up 45.7% YoY)
- Potential impact of API price volatility on CDMO margins
Key Highlights
Standalone Revenue from operations increased 39.5% YoY to ₹400.48 Cr from ₹286.98 Cr.
Standalone Profit After Tax (PAT) surged 58% YoY to ₹32.06 Cr compared to ₹20.30 Cr in Q1 FY26.
Profit Before Tax (PBT) stood at ₹43.03 Cr, a 57.7% increase over the ₹27.29 Cr reported in the year-ago period.
Finance costs rose 45.7% YoY to ₹4.03 Cr, reflecting higher borrowing or interest impacts.
Board initiated a revision of FY26 financial statements to correct errors identified after the May 2026 approval.
👀 What to Watch
Investors should monitor the upcoming board meeting for the specific nature and magnitude of the FY26 financial revisions. While operational growth is robust, the accounting errors require clarity to ensure financial reporting integrity.
Innova Captab FY26 Revenue Up 31% to ₹1,630 Cr; AGM Scheduled for June 29, 2026
Innova Captab has released its FY 2025-26 Integrated Annual Report and scheduled its 22nd AGM for June 29, 2026. The company delivered robust financial performance with revenue growing 31.1% YoY to ₹1,630.02 crore and EBITDA rising 26.3% to ₹250.34 crore. Operational highlights include the successful commercialization of the Kathua facility and obtaining UK-MHRA certification for the Baddi plant. The company also declared an interim dividend of ₹2 per share during the fiscal year.
Key Highlights
Revenue from operations increased 31.1% YoY to ₹1,630.02 crore in FY26.
EBITDA grew 26.3% to ₹250.34 crore, while PAT rose 9.9% to ₹140.92 crore.
Export contribution reached 31.3% across 60+ global markets with 4,200+ products.
Received UK-MHRA GMP compliance for Baddi and PIC/S compliance for the Kathua facility.
Interim dividend of ₹2 per share declared for the financial year.
👀 What to Watch
Investors should monitor the capacity utilization and margin profile of the new Kathua facility as it ramps up. The company's expanding global certifications and 31% revenue growth position it well in the CDMO and branded generics space.
Innova Captab Re-appoints MD, WTD, and Statutory Auditors for 5-Year Terms
Innova Captab's board has approved the re-appointment of key leadership, including Managing Director Vinay Lohariwala and Whole-Time Director Manoj Kumar Lohariwala, for second five-year terms starting March 2027. The company also extended the tenure of B S R & Co. LLP as statutory auditors for another five years until FY 2030-31. Additionally, four independent directors were re-appointed for five-year terms, ensuring board stability through 2032. These appointments are subject to shareholder approval at the upcoming 22nd Annual General Meeting.
Key Highlights
Re-appointment of MD Vinay Lohariwala and WTD Manoj Kumar Lohariwala for 5-year terms (2027-2032)
Statutory Auditor B S R & Co. LLP re-appointed for a second 5-year term (FY 2026-27 to 2030-31)
Grant Thornton Bharat LLP re-appointed as Internal Auditors for the financial year 2026-27
Four Independent Directors re-appointed for 5-year terms starting April 1, 2027
👀 What to Watch
The re-appointment of the founding leadership and reputable audit firms suggests operational and governance continuity. Investors should monitor the upcoming AGM for final shareholder approval of these resolutions.
Innova Captab Re-appoints MD, WTD, and Top-Tier Auditors for 5-Year Terms
Innova Captab has announced the re-appointment of its core leadership, including MD Vinay Lohariwala and WTD Manoj Kumar Lohariwala, for second five-year terms starting March 2027. The board also approved a five-year extension for Statutory Auditors B S R & Co. LLP and a one-year extension for Internal Auditors Grant Thornton Bharat LLP. These appointments, subject to shareholder approval at the 22nd AGM, signal long-term management stability. The leadership team brings over 24-29 years of pharmaceutical industry experience to the company.
Key Highlights
Re-appointment of MD and WTD for 5-year terms effective from March 18, 2027.
B S R & Co. LLP re-appointed as Statutory Auditors for a 5-year block (FY 2026-27 to 2030-31).
Grant Thornton Bharat LLP retained as Internal Auditors for the 2026-27 financial year.
Four Independent Directors re-appointed for 5-year terms starting April 2027.
MD Vinay Lohariwala and WTD Manoj Kumar Lohariwala possess 24 and 29 years of industry experience respectively.
👀 What to Watch
Investors should take confidence in the management continuity and the retention of reputable audit firms. No immediate portfolio changes are necessary based on this governance update.
Innova Captab Re-appoints MD, WTD, and Statutory Auditors for 5-Year Terms
Innova Captab's board has approved the re-appointment of its top leadership, including Managing Director Vinay Lohariwala and Whole-Time Director Manoj Kumar Lohariwala, for five-year terms starting March 2027. The company also ensured continuity in its auditing processes by re-appointing B S R & Co. LLP as statutory auditors for a five-year period until FY 2030-31. Additionally, Grant Thornton Bharat LLP and Gurvinder Chopra and Co. were retained as internal and cost auditors respectively for FY 2026-27. These moves signal a focus on management stability and long-term governance continuity.
Key Highlights
Re-appointment of MD Vinay Lohariwala and WTD Manoj Kumar Lohariwala for 5-year terms (2027-2032)
B S R & Co. LLP re-appointed as Statutory Auditors for a second 5-year term through FY 2030-31
Grant Thornton Bharat LLP retained as Internal Auditors for the financial year 2026-27
Four Independent Directors re-appointed for 5-year terms starting April 1, 2027
Board approved the notice for the 22nd Annual General Meeting (AGM) for FY 2025-26
👀 What to Watch
Investors should view these re-appointments as a sign of management stability and continuity in governance. No immediate action is required as these are standard corporate procedures.
Innova Captab FY26 Revenue Jumps 31% to ₹1,630 Cr; Branded Generics Grows 51%
Innova Captab Limited reported a strong financial performance for FY26, with consolidated revenue rising 31% YoY to ₹1,630 crores. The growth was spearheaded by the Branded Generics segment, which surged 51% to ₹497 crores, while the core CDMO business grew 24% to ₹1,133 crores. Management has guided for a 20% plus revenue growth in the coming years, with expectations that EBITDA and PAT will grow faster than revenue due to operating leverage from the newly ramped-up Jammu facility. The company also achieved significant regulatory milestones, including UK-MHRA and PIC/S certifications, positioning it for regulated international market expansion.
Key Highlights
FY26 Consolidated Revenue grew 31% YoY to ₹1,630 crores, with Q4 revenue up 42% to ₹448 crores.
Branded Generics segment delivered robust 51% growth, contributing ₹497 crores to total revenue.
CDMO business revenue reached ₹1,133 crores, supported by a customer base of over 350 clients.
Full-year EBITDA stood at ₹250.3 crores with a 15.4% margin; PAT grew 10% to ₹140.9 crores.
Exports contributed 31% to total FY26 revenue, aided by new international regulatory approvals.
👀 What to Watch
Investors should focus on the company's ability to maintain its 20%+ growth guidance and the expected margin expansion as the Jammu facility reaches higher utilization. The successful regulatory approvals in the UK and Ukraine provide a strong catalyst for higher-margin export growth in the medium term.
Innova Captab FY26 Revenue Grows 31% to ₹1,630 Cr; Branded Generics Surge 51%
Innova Captab reported a strong performance for FY26 with consolidated revenue growing 31% YoY to ₹1,630 crore, led by a massive 51% jump in the Branded Generics segment. While EBITDA grew 26% to ₹250.3 crore, PAT margins compressed slightly to 8.6% from 10.3% due to increased depreciation and finance costs following the Jammu plant commercialization. The company is successfully ramping up its new Jammu facility (10-15% current utilization) and has secured key international certifications like UK-MHRA and PIC/S, which are expected to drive export growth in regulated markets.
Key Highlights
Annual revenue reached a record ₹1,630 crore (+31% YoY) with Q4 FY26 revenue growing 42% YoY to ₹447.8 crore.
Branded Generics business outperformed with 51% annual growth, while CDMO services grew by 24% to ₹1,133.4 crore.
Jammu facility completed its first full year of operations; utilization is targeted to reach 70-75% over the next 5-6 years.
Secured UK-MHRA certification for Baddi facility and PIC/S compliance for Jammu, enhancing global market access.
Consolidated EBITDA for FY26 stood at ₹250.3 crore with a margin of 15.4%.
👀 What to Watch
Investors should focus on the utilization ramp-up at the Jammu facility and the potential for margin expansion as operating leverage kicks in. The company's shift toward regulated markets and branded generics provides a strong long-term growth trajectory.
Innova Captab Q4 FY26 Revenue Surges 42% YoY to ₹447.8 Cr; FY26 PAT at ₹140.9 Cr
Innova Captab reported a strong top-line growth of 42.3% YoY in Q4 FY26, reaching ₹447.8 crores, driven by momentum in its CDMO and branded generics segments. While EBITDA grew 30.5% to ₹66.7 crores, margins saw a contraction of 130 bps to 14.9% during the quarter. For the full year FY26, the company achieved its highest-ever revenue of ₹1,630 crores, a 31.1% increase over FY25. The company also secured key international certifications including UK-MHRA and PIC/S, positioning it for expansion in regulated global markets.
Key Highlights
Q4 FY26 Revenue grew 42.3% YoY to ₹447.8 Cr; FY26 Revenue reached record ₹1,630 Cr (+31.1%).
Q4 PAT increased by 28.8% YoY to ₹38.1 Cr, while full-year PAT grew 9.9% to ₹140.9 Cr.
EBITDA margins contracted slightly from 16.2% to 14.9% in Q4 and from 15.9% to 15.4% for FY26.
Secured UK-MHRA certification for Baddi facility and PIC/S for Jammu blocks to boost export potential.
Jammu facility completed its first full year of operations and is ramping up with marquee clients.
👀 What to Watch
Investors should focus on the robust revenue growth and the successful ramp-up of the Jammu facility, while monitoring the slight compression in EBITDA margins. The company remains a strong growth play in the CDMO space with improving regulatory credentials for international markets.
Innova Captab Approves FY26 Audited Financial Results with Unmodified Auditor Opinion
Innova Captab Limited's Board of Directors has approved the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The statutory auditors, B S R & Co. LLP, issued an unmodified opinion, confirming the financial statements provide a true and fair view of the company's performance. The consolidated results include performance from subsidiaries such as Univentis Medicare Limited and Sharon Bio-Medicine Limited. Additionally, the board updated the company's Related Party Transactions policy to maintain regulatory compliance.
Key Highlights
Board approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued a declaration of Unmodified Opinion, signifying clean financial reporting.
The consolidated entity includes key subsidiaries Univentis Medicare and Sharon Bio-Medicine Limited.
One subsidiary reported total assets of Rs. 0.34 million and a net loss of Rs. 0.43 million for the year.
Board approved amendments to the Policy on dealing with Related Party Transactions to align with current laws.
👀 What to Watch
Investors should examine the full financial tables on the company's website to evaluate specific growth metrics in revenue and PAT. The clean audit report is a positive sign of corporate governance and financial transparency.
Innova Captab Credit Rating Reaffirmed at 'CARE A; Positive' with Enhanced Limits to ₹466.72 Cr
CARE Ratings has reaffirmed Innova Captab's long-term rating at 'CARE A' while maintaining a 'Positive' outlook, suggesting potential for a future upgrade. The company's total rated bank facilities have been enhanced to ₹466.72 crore, up from ₹409.38 crore previously. Short-term facilities were also reaffirmed at 'CARE A1', reflecting strong liquidity and creditworthiness. This rating action is based on the company's audited FY25 and 9MFY26 performance, indicating sustained financial stability and operational growth.
Key Highlights
Long-term rating reaffirmed at 'CARE A' with a 'Positive' outlook for ₹426.72 crore facilities.
Short-term rating reaffirmed at 'CARE A1' for ₹40.00 crore facilities.
Total bank facility limits enhanced by ₹57.34 crore to a total of ₹466.72 crore.
Rating review considered audited FY25 and unaudited 9MFY26 financial results.
Term loans from HDFC Bank and SBI account for ₹243.72 crore of the total long-term facilities.
👀 What to Watch
The 'Positive' outlook indicates a high probability of a rating upgrade if the company maintains its current growth trajectory. Investors should view this as a sign of improving financial health which could lead to lower borrowing costs in the future.
Innova Captab Wins GST Dispute; ₹15.81 Crore Tax Demand Dropped
Innova Captab Limited has successfully contested a tax demand from the CGST Commissionerate, Shimla. The adjudicating authority dropped the proposed demand of ₹15.81 crore and all associated penal proceedings. The company had filed its response to the October 2025 Show Cause Notice with supporting documents which were found legally sustainable. This concludes the matter with zero liability, removing a significant potential financial hit to the company's balance sheet.
Key Highlights
CGST Commissionerate dropped a tax demand totaling ₹15.81 crore.
The demand was originally raised under Section 74 of the CGST Act, 2017.
The adjudicating authority found the company's legal submissions valid and sustainable.
The matter is now fully concluded with no financial liability or penalties for Innova Captab.
👀 What to Watch
Investors should view this as a positive resolution of a significant contingent liability. No further action is required as the legal risk has been successfully mitigated.
Innova Captab Q3 FY26 Revenue Surges 42% to ₹450 Cr; Branded Generics Grow 79%
Innova Captab reported a strong Q3 FY26 with consolidated revenue growing 42.3% YoY to ₹450.3 crores, driven by a massive 79% surge in the branded generics segment. The CDMO business also showed steady growth of 29% YoY, contributing ₹298.7 crores to the top line. The newly commissioned Jammu facility is scaling up well, contributing ₹89 crores this quarter and nearing EBITDA break-even. Profitability remained robust with EBITDA rising 39.6% to ₹71.1 crores, maintaining a healthy margin of 15.8%.
Key Highlights
Consolidated Q3 revenue reached ₹450.3 crores, a 42.3% YoY increase from ₹316.4 crores.
Branded generics segment grew 79% YoY to ₹151.6 crores due to aggressive domestic and international expansion.
Jammu facility revenue rose to ₹89 crores from ₹60 crores in the previous quarter, nearing EBITDA break-even.
EBITDA increased by 39.6% YoY to ₹71.1 crores with margins steady at 15.8%.
Exports formed 35% of Q3 revenue mix, supported by new UK-MHRA and PIC/S certifications.
👀 What to Watch
Investors should monitor the ramp-up of the Jammu facility, which has a potential revenue capacity of ₹1,400+ crores at optimum utilization. The strong growth in high-margin branded generics and expansion into regulated export markets provides a positive long-term outlook.
Innova Captab Declares ₹2 Interim Dividend; Sets January 30 as Record Date
Innova Captab Limited has declared an interim dividend of ₹2 per equity share, representing 20% of the face value of ₹10 each for FY 2025-26. The company has fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. In compliance with the Finance Act 2020, the dividend is taxable, and the company will deduct Tax at Source (TDS) based on the residential status and documentation provided by shareholders. Shareholders are required to submit relevant tax forms by 5:00 PM on the record date to ensure appropriate tax treatment.
Key Highlights
Interim dividend declared at ₹2 per equity share (20% of face value).
Record date for dividend eligibility is fixed as Friday, January 30, 2026.
TDS will be deducted based on documentation submitted via KFintech portal by Jan 30.
Dividend payments will be made exclusively through electronic modes like NEFT and RTGS.
The board meeting declaring this dividend was held on January 23, 2026.
👀 What to Watch
Investors should ensure their bank account details are updated with their DP and submit Form 15G/15H by January 30 to minimize TDS impact.
Innova Captab Q3 FY26 Revenue Surges 42% YoY to ₹450 Cr; Branded Generics Up 79%
Innova Captab reported a strong Q3 FY26 with revenue growing 42.3% YoY to ₹450.3 crore, driven by a massive 79% jump in the Branded Generics segment. EBITDA increased by 39.6% to ₹71.1 crore, though margins slightly contracted to 15.8% from 16.1% due to higher employee and material costs. The company achieved significant regulatory milestones, including UK-MHRA and PIC/s GMP certifications, which are expected to boost international market access. The newly commercialized Jammu facility is ramping up, providing a long-term growth runway with significant tax incentives.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 42.3% YoY to ₹450.3 crore, while 9M FY26 revenue reached ₹1,182.2 crore.
Branded Generics segment showed stellar performance with 79% YoY growth in Q3, reaching ₹151.6 crore.
EBITDA for the quarter rose 39.6% to ₹71.1 crore, maintaining a healthy margin of 15.8%.
Export contribution increased to 35% of total revenue in Q3 FY26, supported by new global GMP certifications.
The Jammu manufacturing facility, commercialized in Jan 2025, is eligible for GST-linked incentives totaling 300% of investment over 10 years.
👀 What to Watch
Investors should monitor the capacity utilization ramp-up at the Jammu facility and the margin trajectory as the high-growth Branded Generics business scales. The stock remains a strong play on the Indian CDMO and generic export themes.
Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹450.3 Cr; PAT Rises 23%
Innova Captab Limited delivered a robust performance in Q3 FY26, with revenue from operations surging 42.3% YoY to ₹450.3 crores. EBITDA followed suit with a 39.6% increase to ₹71.1 crores, although margins contracted slightly by 30 bps to 15.8%. The company reported a 23.2% growth in PAT for the quarter, reaching ₹42.1 crores. Additionally, the receipt of UK-MHRA and PIC/s certifications for its manufacturing units strengthens its international market prospects.
Key Highlights
Q3 FY26 Revenue from operations grew 42.3% YoY to ₹450.3 crores.
EBITDA for the quarter increased 39.6% YoY to ₹71.1 crores with a 15.8% margin.
Profit After Tax (PAT) for Q3 FY26 rose 23.2% YoY to ₹42.1 crores.
Received UK-MHRA GMP certification for Baddi unit and PIC/s compliance for Jammu facility.
9M FY26 Revenue reached ₹1182.2 crores, up 27.3% compared to 9M FY25.
👀 What to Watch
The strong top-line growth and new global regulatory approvals suggest a positive outlook for the CDMO and export business. Investors should maintain a positive stance while monitoring if the company can improve its margins in upcoming quarters.
